NDA 205874 · Keryx Biopharms
Auryxia
Ferric Citrate · Oral
Last checked: Nov 20, 2026Latest source record: Jan 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Sep 5, 2014
Approved uses
2
Original approval plus efficacy supplements
Registered trials
553
145 Phase 3, 57 recruiting
FAERS reports
2,203
775 serious, 261 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 29, 2026.
Auryxia is a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. ( 1 ) Auryxia is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. ( 1 ) 1.1 Hyperphosphatemia in Chronic Kidney Disease on Dialysis Auryxia is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. 1.2 Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Auryxia is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.
Mechanism: Hyperphosphatemia in Chronic Kidney Disease on Dialysis Ferric iron binds dietary phosphate in the GI tract and precipitates as ferric phosphate. This compound is insoluble and is excreted in the stool. By binding phosphate in the GI tract and decreasing absorption, ferric citrate lowers the phosphate concentration in the serum. Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis Ferric iron is reduced from the ferric to the ferrous form by ferric reductase in the GI tract. After transport through the enterocytes into the blood, oxidized ferric iron circulates bound to the plasma...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 6, 2017 Supplement 13 · Efficacy LabelLetter
- Sep 5, 2014 Original approval · Type 5 - New Formulation or New Manufacturer Summary ReviewLetterLabel
1 products under this application
- AURYXIA · FERRIC CITRATE EQ 210MG IRON · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ferric" as an intervention, any sponsor and status, largest first.
- Prevention of Iron Deficiency Anemia Post-deliveryPivotal-lookingCompleted
NICHD Global Network for Women's and Children's HealthResearch network
NCT05590260 · 4,857 participants · Start May 30, 2023 · Primary completion Mar 10, 2025
Drug: Ferric carboxymaltose (FCM) and folic acid tablets; Oral iron tablets and folic acid tablets · For: Postpartum Anemia
Sites: Dhaka, Bangladesh; Kinshasa, Democratic Republic of the Congo; Guatemala City, Guatemala · 8 sites in all
- Reducing Anemia in Pregnancy in India: the RAPIDIRON TrialPivotal-lookingCompleted
Thomas Jefferson UniversityAcademic, hospital or other
NCT05358509 · 4,368 participants · Start Mar 15, 2021 · Primary completion Dec 14, 2023
Drug: Ferric carboxymaltose; Iron isomaltoside and 1 more · For: Iron Deficiency Anemia; Infant, Low Birth Weight; Anemia of Pregnancy
Sites: Bagalkot, India; Belagavi, India; Rāichūr, India · 4 sites in all
- Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyPivotal-lookingCompleted
American Regent, Inc.Industry
NCT03037931 · 3,065 participants · Start Mar 15, 2017 · Primary completion Feb 2, 2023
Drug: Ferric Carboxymaltose; Placebo · For: Heart Failure; Iron-deficiency
Sites: Alexander City, Alabama; Auburn, Alabama; Mobile, Alabama · 345 sites in all
- Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum DepressionPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06833788 · 2,860 participants (planned) · Start Oct 22, 2025 · Primary completion Jun 22, 2028
Drug: Ferric carboxymaltose IV; TIMOFÉROL® · For: Postpartum Depression (PPD)
Sites: Paris, France
- Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal FunctionPivotal-lookingCompleted
American Regent, Inc.Industry
NCT00981045 · 2,561 participants · Start Aug 2009 · Primary completion Jul 2011
Drug: Ferric Carboxymaltose (FCM); Iron Sucrose (Venofer) · For: Iron Deficiency Anemia; Impaired Renal Function
Sites: Norristown, Pennsylvania
- Iron Supplementation in TAVI and SAVR Patients With Iron DeficiencyPivotal-lookingStatus unknown
Hospital de Santa Cruz, PortugalAcademic, hospital or other
NCT04786769 · 2,500 participants (planned) · Start Jan 2022 · Primary completion Jan 2025
Drug: Ferric carboxymaltose · For: Aortic Stenosis; Iron-deficiency
- Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum PatientsPivotal-lookingCompleted
American Regent, Inc.Industry
NCT00548860 · 2,018 participants · Start Oct 2007 · Primary completion Mar 2009
Drug: Ferric Carboxymaltose; Standard Medical Care (SMC) · For: Anemia
Sites: Norristown, Pennsylvania
- A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)Pivotal-lookingCompleted
AMAG Pharmaceuticals, Inc.Industry
NCT02694978 · 2,014 participants · Start Feb 29, 2016 · Primary completion Jan 16, 2017
Drug: Ferumoxytol; FCM · For: Iron Deficiency Anemia
Sites: Huntsville, Alabama; Tucson, Arizona; Anaheim, California · 127 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea310
- serum ferritin increased228
- transferrin saturation increased169
- faeces discoloured118
- death112
- constipation83
- nausea71
- drug ineffective69
- vomiting65
- chronic kidney disease59
- end stage renal disease58
- pruritus55
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2011 | 1 |
| 2014 | 2 |
| 2015 | 131 |
| 2016 | 176 |
| 2017 | 408 |
| 2018 | 313 |
| 2019 | 252 |
| 2020 | 276 |
| 2021 | 233 |
| 2022 | 130 |
| 2023 | 62 |
| 2024 | 95 |
| 2025 | 85 |
| 2026 | 38 |
Recalls
4 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Dec 9, 2020 · Class II · Terminated
CGMP Deviations
Jul 10, 2020 · Class II · Terminated
cGMP deviations: Lots recalled were not manufactured in conformance with the FDA-approved manufacturing process for Auryxia.
Dec 12, 2017 · Class III · Terminated
Presence of Foreign Substance: Reports have been received of damaged StripPax packets containing silica gel desiccant potentially allowing the silica gel granules to make contact with Auryxia tablets in the bottle.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Auryxia (Ferric Citrate)
2024 spending
$132M
Beneficiaries
17,163
72,567 claims
Per beneficiary
$7,664
$7.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $196,402,947 |
| 2021 | $199,110,901 |
| 2022 | $194,683,928 |
| 2023 | $182,627,699 |
| 2024 | $131,543,849 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Use of Vital Pulp Therapies in Primary Teeth 2024.
Coll JA, Dhar V, Chen CY, et al. · Pediatr Dent 2024 · Systematic Review, Meta-Analysis
- Primary Tooth Vital Pulp Treatment Interventions: Systematic Review and Meta-Analyses.
Coll JA, Dhar V, Chen CY, et al. · Pediatr Dent 2023 · Meta-Analysis, Systematic Review
- Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
Ponikowski P, Kirwan BA, Anker SD, et al. · Lancet 2020 · Multicenter Study, Randomized Controlled Trial
- Primary Tooth Vital Pulp Therapy: A Systematic Review and Meta-analysis.
Coll JA, Seale NS, Vargas K, et al. · Pediatr Dent 2017 · Meta-Analysis, Systematic Review
- Pulp treatment for extensive decay in primary teeth.
Smaïl-Faugeron V, Glenny AM, Courson F, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Diagnosis and treatment of iron-deficiency anemia in gastrointestinal bleeding: A systematic review.
Cotter J, Baldaia C, Ferreira M, et al. · World J Gastroenterol 2020 · Meta-Analysis, Systematic Review
Sponsor: Keryx Biopharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.